Periodontal DiseasePhase 4NCT07605767
Adjunctive Topical Melatonin Gel in Non-Surgical Periodontal Therapy for Periodontitis
A Phase 4 study testing Topical 5% Melatonin Gel in people with Periodontal Disease and Melatonin, run by Liaquat College of Medicine and Dentistry at 1 site in Pakistan.
Trial summary
The goal of this clinical trial is to evaluate the clinical effectiveness of adjunctive topical melatonin gel when used with non-surgical periodontal therapy (NSPT) in adult patients with periodontitis. Read more about this study
- Who is it for?
- Ages 18 to 45 years
- Conditions the study is for
- Periodontal Disease, Melatonin
- What is being tested?
- Topical 5% Melatonin Gel
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 30 participants
- Where
- 1 sitePakistan
- Study dates
- 3 Nov 2025to 10 Apr 2026
- Phase
- Phase 4
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 45 years
- All sexes
- No healthy volunteers
- Adult
Who may be able to join
- Patients aged 18-45 years
- Patients diagnosed with periodontitis with clinical attachment loss (CAL) between 3-4 mm
- Systemically healthy individuals
- Patients with controlled systemic diseases (ASA I \& II)
- Patients willing to participate and provide informed consent
Who cannot join
- Smokers or tobacco users
- Pregnant or lactating females
- Patients with uncontrolled diabetes mellitus (HbA1c >6.5%)
- Patients who received periodontal therapy within the last 6 months
- Patients who used antibiotics, anti-inflammatory drugs, sleeping pills, or antioxidant supplements within the last 6 months
- Individuals working night shifts -Patients with mental illness or neuromuscular disorders-
- Patients unwilling to participate or unable to comply with follow-up visits
Trial locations and contacts
1 site in 1 country.
Pakistan1 site
Liaquat College of Medicine and Dentistry
Karachi, Sindh, 7290
About this study
Official title: Evaluation of Clinical Outcomes of Adjunctive Topical Melatonin Gel in Non-Surgical Periodontal Therapy: A Randomized Placebo-Controlled Trial in Karachi
The goal of this clinical trial is to evaluate the clinical effectiveness of adjunctive topical melatonin gel when used with non-surgical periodontal therapy (NSPT) in adult patients with periodontitis. This study includes systemically healthy or medically controlled patients aged 18-45 years who are diagnosed with periodontitis and attend the Department of Periodontology at Liaquat College of Medicine \& Dentistry, Karachi.
The main questions it aims to answer are:
Read more
- Does adjunctive topical 5% melatonin gel improve clinical attachment level (CAL) compared to placebo after NSPT?
- Does adjunctive topical 5% melatonin gel improve plaque index (PI), gingival index (GI), and periodontal pocket depth (PPD) compared to placebo after NSPT? Researchers will compare patients receiving NSPT with topical melatonin gel to patients receiving NSPT with placebo gel to determine whether melatonin provides additional clinical benefits in periodontal therapy.
Participants will:
- Undergo baseline periodontal examination, including assessment of plaque index, gingival index, periodontal pocket depth, and clinical attachment level.
- Receive non-surgical periodontal therapy (scaling and root planing).
- Be randomly assigned to receive either 5% topical melatonin gel or placebo gel applied intra-pocket.
- Attend follow-up visits for gel application and monitoring.
- Undergo reassessment of clinical periodontal parameters after three months.
- Be monitored for any adverse effects during the study period. This study is a randomized, double-blind, placebo-controlled clinical trial evaluating the role of topical melatonin gel as an adjunct to conventional non-surgical periodontal therapy in improving periodontal clinical outcomes.
Read the detailed description
Periodontitis is a chronic inflammatory disease affecting the supporting structures of the teeth and is one of the leading causes of tooth loss worldwide. The disease is initiated by pathogenic bacterial biofilm and progresses through a complex host inflammatory response that results in destruction of the periodontal ligament, alveolar bone loss, periodontal pocket formation, and clinical attachment loss. In Pakistan, periodontitis has a high prevalence and represents a significant oral health burden affecting quality of life and overall health.
Non-surgical periodontal therapy (NSPT), consisting primarily of scaling and root planing, is considered the gold standard treatment for periodontitis. NSPT effectively reduces microbial load and improves periodontal clinical parameters, including plaque index (PI), gingival index (GI), probing pocket depth (PPD), and clinical attachment level (CAL). However, despite the effectiveness of mechanical debridement, complete resolution of inflammation and periodontal tissue regeneration may not always be achieved, leading researchers to investigate adjunctive therapeutic approaches.
Melatonin is a naturally occurring hormone mainly secreted by the pineal gland and is known for regulating circadian rhythm. In addition to its physiologic role, melatonin possesses antioxidant, anti-inflammatory, immunomodulatory, and bone-regenerative properties. Experimental and clinical studies have suggested that melatonin may reduce oxidative stress, regulate inflammatory mediators, inhibit tissue destruction, and promote osteoblastic activity and collagen formation. These biologic effects indicate its potential usefulness as an adjunctive agent in periodontal therapy.
Previous international studies have demonstrated promising results with topical melatonin application in periodontal treatment, showing improvements in inflammatory parameters and periodontal healing. However, there is limited evidence regarding its clinical effectiveness in the Pakistani population, and no randomized placebo-controlled clinical trial has been conducted locally to evaluate its adjunctive role with NSPT.
This study is designed as a randomized, double-blind, placebo-controlled clinical trial to assess the clinical outcomes of adjunctive topical melatonin gel in patients undergoing non-surgical periodontal therapy. A total of 30 patients diagnosed with periodontitis will be recruited from the Department of Periodontology at Liaquat College of Medicine \& Dentistry, Karachi. Eligible participants will include adults aged 18-45 years who are systemically healthy or medically controlled and diagnosed with periodontitis with clinical attachment loss between 3-4 mm.
Participants will be randomly allocated into two groups. The experimental group will receive NSPT followed by intra-pocket application of 5% topical melatonin gel, while the control group will receive NSPT followed by placebo gel application. Both gels will be similar in appearance to maintain blinding. The study will follow a double-blind design in which both participants and the primary investigator assessing outcomes will remain unaware of group allocation.
Clinical periodontal parameters, including Plaque Index (PI), Gingival Index (GI), Probing Pocket Depth (PPD), and Clinical Attachment Level (CAL), will be recorded at baseline and reassessed after three months. Participants will also be monitored for adverse effects such as burning sensation, taste alteration, or mucosal irritation throughout the study period.
The primary objective of the study is to compare the clinical effectiveness of adjunctive topical melatonin gel with placebo in improving periodontal clinical outcomes following NSPT. The findings of this study may contribute to the growing evidence regarding host-modulatory therapy in periodontics and help determine whether topical melatonin can serve as a cost-effective adjunctive treatment option in periodontal care within the local population.
- Conditions
- Periodontal Disease, Melatonin
- Being tested
- Topical 5% Melatonin Gel, Placebo
- Medical subject headings
- Periodontal Diseases
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Topical 5% Melatonin GelDrug
A locally delivered 5% topical melatonin gel applied intra-pocket as an adjunct to non-surgical periodontal therapy (scaling and root planing). The gel was prepared using a standardized gel base and administered weekly during the first month of treatment. Melatonin gel was used to evaluate its potential anti-inflammatory, antioxidant, and periodontal healing effects in patients with periodontitis.
PlaceboOther
A locally delivered placebo gel applied intrapocketly as an adjunct to non-surgical periodontal therapy (scaling and root planing). The placebo gel contained the same gel base and appearance as the experimental melatonin gel but without the active melatonin ingredient. It was administered weekly during the first month of treatment to serve as a control for comparison of clinical periodontal outcomes.
| Study group | Role | What they receive |
|---|---|---|
| Test Group | Experimental | Participants in the experimental group received non-surgical periodontal therapy (scaling and root planing) followed by intrapocket application of 5% topical melatonin gel. The gel was applied weekly during the first month after therapy. Clinical periodontal parameters, including Plaque Index (PI), Gingival Index (GI), Probing Pocket Depth (PPD), and Clinical Attachment Level (CAL), were evaluated at baseline and after three months to assess treatment outcomes. Receives: Drug: Topical 5% Melatonin Gel |
| Control Group | Placebo comparator | Participants in the control group received non-surgical periodontal therapy (scaling and root planing) followed by intrapocket application of placebo gel identical in appearance to the melatonin gel but without the active ingredient. The placebo gel was applied weekly during the first month after therapy. Clinical periodontal parameters, including Plaque Index (PI), Gingival Index (GI), Probing Pocket Depth (PPD), and Clinical Attachment Level (CAL), were evaluated at baseline and after three months to assess treatment outcomes. Receives: Other: Placebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in Probing Pocket Depth (PPD)
Measured using a UNC-15 periodontal probe in millimeters from baseline to 3 months following non-surgical periodontal therapy.
Measured: 3 Months
Change in Clinical Attachment Level (CAL)
Measured using a UNC-15 periodontal probe in millimeters from baseline to 3 months following non-surgical periodontal therapy.
Measured: 3 Months
Secondary outcomes (2)
Change in Gingival Index (GI)
Assessed using standardized gingival inflammation scoring from baseline to 3 months following therapy.
Measured: 3 Months
Change in Plaque Index (PI)
Assessed using standardized plaque accumulation scoring from baseline to 3 months following therapy.
Measured: 3 Months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted26 May 2026
- Study start3 Nov 2025
- Primary completion5 Jan 2026
- Study completion10 Apr 2026
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Periodontal DiseaseStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 4
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Participant, Outcomes assessor
- Enrolment
- 30 participants (actual)
Sponsor and investigators
- Lead sponsor
- Liaquat College of Medicine and Dentistry
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Ishma Binte Saeed, Liaquat College of Medicine and Dentistry
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07605767
- Sponsor's protocol ID
- ASRB/No./09930/MS
- Status last verified
- May 2026
- First submitted
- 29 Apr 2026
- Last updated
- 26 May 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 26 May 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Evaluation of Clinical Outcomes of Adjunctive Topical Melatonin Gel in Non-Surgical Periodontal Therapy: A Randomized Placebo-Controlled Trial in Karachi
- ClinicalTrials.gov ID
- NCT07605767
- Acronym / sponsor ID
- ASRB/No./09930/MS
- Conditions
- Periodontal Disease, Melatonin
- Phase
- Phase 4
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 30 participants (actual)
- Lead sponsor
- Liaquat College of Medicine and DentistryUniversity, hospital or other
- Study start
- 3 Nov 2025 (actual)
- Primary completion
- 5 Jan 2026 (actual)
- Study completion
- 10 Apr 2026 (actual)
- First posted
- 26 May 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this clinical trial is to evaluate the clinical effectiveness of adjunctive topical melatonin gel when used with non-surgical periodontal therapy (NSPT) in adult patients with periodontitis. This study includes systemically healthy or medically controlled patients aged 18-45 years who are diagnosed with periodontitis and attend the Department of Periodontology at Liaquat College of Medicine \& Dentistry, Karachi.
The main questions it aims to answer are:
- Does adjunctive topical 5% melatonin gel improve clinical attachment level (CAL) compared to placebo after NSPT?
- Does adjunctive topical 5% melatonin gel improve plaque index (PI), gingival index (GI), and periodontal pocket depth (PPD) compared to placebo after NSPT? Researchers will compare patients receiving NSPT with topical melatonin gel to patients receiving NSPT with placebo gel to determine whether melatonin provides additional clinical benefits in periodontal therapy.
Participants will:
- Undergo baseline periodontal examination, including assessment of plaque index, gingival index, periodontal pocket depth, and clinical attachment level.
- Receive non-surgical periodontal therapy (scaling and root planing).
- Be randomly assigned to receive either 5% topical melatonin gel or placebo gel applied intra-pocket.
- Attend follow-up visits for gel application and monitoring.
- Undergo reassessment of clinical periodontal parameters after three months.
- Be monitored for any adverse effects during the study period. This study is a randomized, double-blind, placebo-controlled clinical trial evaluating the role of topical melatonin gel as an adjunct to conventional non-surgical periodontal therapy in improving periodontal clinical outcomes.
Detailed description
Periodontitis is a chronic inflammatory disease affecting the supporting structures of the teeth and is one of the leading causes of tooth loss worldwide. The disease is initiated by pathogenic bacterial biofilm and progresses through a complex host inflammatory response that results in destruction of the periodontal ligament, alveolar bone loss, periodontal pocket formation, and clinical attachment loss. In Pakistan, periodontitis has a high prevalence and represents a significant oral health burden affecting quality of life and overall health.
Non-surgical periodontal therapy (NSPT), consisting primarily of scaling and root planing, is considered the gold standard treatment for periodontitis. NSPT effectively reduces microbial load and improves periodontal clinical parameters, including plaque index (PI), gingival index (GI), probing pocket depth (PPD), and clinical attachment level (CAL). However, despite the effectiveness of mechanical debridement, complete resolution of inflammation and periodontal tissue regeneration may not always be achieved, leading researchers to investigate adjunctive therapeutic approaches.
Melatonin is a naturally occurring hormone mainly secreted by the pineal gland and is known for regulating circadian rhythm. In addition to its physiologic role, melatonin possesses antioxidant, anti-inflammatory, immunomodulatory, and bone-regenerative properties. Experimental and clinical studies have suggested that melatonin may reduce oxidative stress, regulate inflammatory mediators, inhibit tissue destruction, and promote osteoblastic activity and collagen formation. These biologic effects indicate its potential usefulness as an adjunctive agent in periodontal therapy.
Previous international studies have demonstrated promising results with topical melatonin application in periodontal treatment, showing improvements in inflammatory parameters and periodontal healing. However, there is limited evidence regarding its clinical effectiveness in the Pakistani population, and no randomized placebo-controlled clinical trial has been conducted locally to evaluate its adjunctive role with NSPT.
This study is designed as a randomized, double-blind, placebo-controlled clinical trial to assess the clinical outcomes of adjunctive topical melatonin gel in patients undergoing non-surgical periodontal therapy. A total of 30 patients diagnosed with periodontitis will be recruited from the Department of Periodontology at Liaquat College of Medicine \& Dentistry, Karachi. Eligible participants will include adults aged 18-45 years who are systemically healthy or medically controlled and diagnosed with periodontitis with clinical attachment loss between 3-4 mm.
Participants will be randomly allocated into two groups. The experimental group will receive NSPT followed by intra-pocket application of 5% topical melatonin gel, while the control group will receive NSPT followed by placebo gel application. Both gels will be similar in appearance to maintain blinding. The study will follow a double-blind design in which both participants and the primary investigator assessing outcomes will remain unaware of group allocation.
Clinical periodontal parameters, including Plaque Index (PI), Gingival Index (GI), Probing Pocket Depth (PPD), and Clinical Attachment Level (CAL), will be recorded at baseline and reassessed after three months. Participants will also be monitored for adverse effects such as burning sensation, taste alteration, or mucosal irritation throughout the study period.
The primary objective of the study is to compare the clinical effectiveness of adjunctive topical melatonin gel with placebo in improving periodontal clinical outcomes following NSPT. The findings of this study may contribute to the growing evidence regarding host-modulatory therapy in periodontics and help determine whether topical melatonin can serve as a cost-effective adjunctive treatment option in periodontal care within the local population.
Study design
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Test Group | Experimental | Drug: Topical 5% Melatonin GelParticipants in the experimental group received non-surgical periodontal therapy (scaling and root planing) followed by intrapocket application of 5% topical melatonin gel. The gel was applied weekly during the first month after therapy. Clinical periodontal parameters, including Plaque Index (PI), Gingival Index (GI), Probing Pocket Depth (PPD), and Clinical Attachment Level (CAL), were evaluated at baseline and after three months to assess treatment outcomes. |
| Control Group | Placebo comparator | Other: PlaceboParticipants in the control group received non-surgical periodontal therapy (scaling and root planing) followed by intrapocket application of placebo gel identical in appearance to the melatonin gel but without the active ingredient. The placebo gel was applied weekly during the first month after therapy. Clinical periodontal parameters, including Plaque Index (PI), Gingival Index (GI), Probing Pocket Depth (PPD), and Clinical Attachment Level (CAL), were evaluated at baseline and after three months to assess treatment outcomes. |
Who may qualify
- Ages
- 18 to 45 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult
Key inclusion criteria (5 listed)
- Patients aged 18-45 years
- Patients diagnosed with periodontitis with clinical attachment loss (CAL) between 3-4 mm
- Systemically healthy individuals
- Patients with controlled systemic diseases (ASA I \& II)
- Patients willing to participate and provide informed consent
Key exclusion criteria (7 listed)
- Smokers or tobacco users
- Pregnant or lactating females
- Patients with uncontrolled diabetes mellitus (HbA1c >6.5%)
- Patients who received periodontal therapy within the last 6 months
- Patients who used antibiotics, anti-inflammatory drugs, sleeping pills, or antioxidant supplements within the last 6 months
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Topical 5% Melatonin GelA locally delivered 5% topical melatonin gel applied intra-pocket as an adjunct to non-surgical periodontal therapy (scaling and root planing). The gel was prepared using a standardized gel base and administered weekly during the first month of treatment. Melatonin gel was used to evaluate its potential anti-inflammatory, antioxidant, and periodontal healing effects in patients with periodontitis. | Drug | Test Group |
| PlaceboA locally delivered placebo gel applied intrapocketly as an adjunct to non-surgical periodontal therapy (scaling and root planing). The placebo gel contained the same gel base and appearance as the experimental melatonin gel but without the active melatonin ingredient. It was administered weekly during the first month of treatment to serve as a control for comparison of clinical periodontal outcomes. | Other | Control Group |
Primary outcome
Change in Probing Pocket Depth (PPD)
Time frame: 3 Months
Measured using a UNC-15 periodontal probe in millimeters from baseline to 3 months following non-surgical periodontal therapy.
Change in Clinical Attachment Level (CAL)
Time frame: 3 Months
Measured using a UNC-15 periodontal probe in millimeters from baseline to 3 months following non-surgical periodontal therapy.
2 secondary outcomes
Change in Gingival Index (GI)
Time frame: 3 Months
Change in Plaque Index (PI)
Time frame: 3 Months
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 26 May 2026.
- Individual participant dataSharing planned: No
Related trials for Periodontal Disease
Not yet recruitingObservational study
Periodontal Status and Biomarkers in MASLD
Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
Recruiting
Thermosensitive Hyaluronic Gel With Octenidine as an Adjunctive to Subgingival Instrumentation
Periodontal Disease
Active, not recruitingObservational study
A Retrospective Comparative Evaluation of Omega-3 and Resveratrol Supplementation in Patients With Periodontitis
Periodontitis
Recruiting
Effects of Different Activation Techniques on Antimicrobial Photodynamic Therapy in Apical Periodontitis
Apical Periodontitis, Endodontic Retreatment
Recruiting
Ozone Gel Versus Chlorohexidine Gel as an Adjunct to Non-Surgical Treatment of Stage II Periodontitis Grade B Among Smokers Patients
Ozone Gel, Chlorohexidine Gel
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 4 study testing Topical 5% Melatonin Gel in people with Periodontal Disease and Melatonin, run by Liaquat College of Medicine and Dentistry at 1 site in Pakistan.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 26 May 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Pakistan. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change in Probing Pocket Depth (PPD) (time frame: 3 Months). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 26 May 2026.